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Abstract
New Zealand Māori have a considerably higher incidence of gastric cancer compared to non-Māori, and are one of the few 
populations worldwide with a higher prevalence of diffuse-type disease. Pathogenic germline CDH1 mutations are causative 
of hereditary diffuse gastric cancer, a cancer predisposition syndrome primarily characterised by an extreme lifetime risk of 
developing diffuse gastric cancer. Pathogenic CDH1 mutations are well described in Māori families in New Zealand. How-
ever, the contribution of these mutations to the high incidence of gastric cancer is unknown. We have used next-generation 
sequencing, Sanger sequencing, and Multiplex Ligation-dependent Probe Amplification to examine germline CDH1 in an 
unselected series of 94 Māori gastric cancer patients and 200 healthy matched controls. Overall, 18% of all cases, 34% of 
cases diagnosed with diffuse-type gastric cancer, and 67% of cases diagnosed aged less than 45 years carried pathogenic 
CDH1 mutations. After adjusting for the effect of screening known HDGC families, we estimate that 6% of all advanced 
gastric cancers and 13% of all advanced diffuse-type gastric cancers would carry germline CDH1 mutations. Our results 
demonstrate that germline CDH1 mutations are a significant contributor to the high frequency of diffuse gastric cancer in 
New Zealand Māori.
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Introduction
Although the worldwide incidence of gastric cancer has 
declined steadily over the past 4–5 decades, it remains the 
5th most common cancer type worldwide [1]. The vast 
majority of gastric cancers are adenocarcinomas, which 
can be further subdivided into intestinal and diffuse type 
according to the Lauren classification [2]. Intestinal-type 
gastric cancer is more common in older patients and is more 
strongly associated with exposure to environmental risk fac-
tors, whereas diffuse-type gastric cancer is more associated 
with an earlier onset and a family history of the disease [2]. 
Typically, intestinal-type tumours predominate high-inci-
dence geographic areas and account for much of the varia-
tion in gastric cancer incidence between groups [3].
As a whole, New Zealand is a country with a low inci-
dence of gastric cancer [1]. However, Māori, the indigenous 
people of New Zealand (who comprise almost 15% of the 
total 4.5 million population) [4], experience disproportionate 
rates of gastric cancer compared to non-Māori [5]. The most 
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recent data from the New Zealand Cancer Registry (NZCR) 
show Māori registration rates for gastric cancer are more 
than three times that of non-Māori (15.8 vs. 4.8 per 100,000, 
respectively) [6]. Additionally, on average, Māori develop 
gastric cancer 10 years younger than non-Māori and are one 
of the few populations worldwide with a higher incidence of 
diffuse-type disease [7, 8]. The reasons for these differences 
are largely unexplained.
Germline mutations in the gene CDH1, encoding the cell 
adhesion protein E-cadherin, are causative of the autosomal 
dominant cancer predisposition syndrome Hereditary Dif-
fuse Gastric Cancer (HDGC) [9, 10]. Mutation carriers are 
predisposed to an extreme risk of developing diffuse-type 
gastric cancer from a relatively young age [11]. Based on 
HDGC families from around the world, the current estimated 
cumulative risk of developing diffuse gastric cancer by the 
age of 80 years is 70% for males (95% CI 59–80%) and 56% 
for females (95% CI 44–69%) [11]. In addition, women car-
rying CDH1 mutations have a 42% (95% CI 23–68%) cumu-
lative risk of developing lobular breast cancer by the age of 
80 years [11]. In Family A, the large Māori kindred in which 
the first pathogenic CDH1 mutation was identified, the over-
all penetrance of diffuse gastric cancer is approximately 70% 
[9]. In Western populations, it is estimated that 1% of all gas-
tric cancers are caused by germline CDH1 mutations [12].
Germline CDH1 mutations have been well documented 
in Māori families in New Zealand [8, 9]. However, the con-
tribution CDH1 mutations make to the high incidence of 
diffuse gastric cancer in Māori is unknown. This paper pre-
sents the findings on the prevalence of cases with pathogenic 
CDH1 mutations from a case-control study of gastric cancer 
conducted in the Māori population.
Materials and methods
Study participants
Study participants were from a New Zealand Māori popu-
lation-based case-control study examining factors associ-
ated with gastric cancer risk [13]. Briefly, all Māori gastric 
cancers reported to the NZCR between 1 February 2009 
and 31 October 2013 were followed up, with a sample of 
whole blood obtained from consenting participants who 
were well enough. The control group were a population-
based random sample of individuals aged over 18 years who 
self-identified as Māori on the New Zealand electoral roll. 
Sequenced controls were matched to cases by gender and 
5 year age bands. The study was granted ethics approval 
by the New Zealand Multi-region Ethics Committee (ref: 
MEC/08/08/102/AM03). Informed written consent was 
obtained from all study participants. Full details describing 
the identification of study participants and the collection 
of samples are described in Ellison-Loschmann et al. [13].
Sequencing library preparation
Duel-indexed amplicon sequencing libraries for germline 
CDH1 were generated using a novel two-step PCR strategy. 
Briefly, in the first PCR step, the coding exons of CDH1, 
including their intron–exon borders and the proximal pro-
moter, were amplified. CDH1 primers were designed with 
an additional 18 bp of known non-specific sequence that 
was used as a priming site for the second reaction (Sup-
plementary Table 1). PCR products from the same study 
participant were pooled in equal volumes and purified using 
AMPure XP beads. In the second PCR step, pooled PCR 
products were amplified using a unique pair of indexed 
primers designed to add sequences necessary for multiplex 
sequencing on an Illumina MiSeq (Supplementary Table 2). 
Full details describing the PCR reactions are available upon 
request.
Sample specific libraries were pooled and sequenced in 
batches across multiple MiSeq runs. To prepare the sequenc-
ing libraries, sample libraries were pooled in equal volumes, 
purified using AMPure XP beads, and quantified with the 
Qubit dsDNA HS Assay Kit. Sequencing libraries were run 
on a DNA7500 Bioanlayzer chip to determine the average 
library size. Libraries were sequenced on an Illumina MiSeq 
using either V2-500 cycle or V3-600 cycle reagent kits.
Sequence analysis and annotation
Raw paired end reads were cleaned with Trimmomatic 
v.0.35 [14]. Cleaned reads were aligned to the human refer-
ence genome (GRCh37/hg19) using the Burrows–Wheeler 
Aligner v.0.7.10 [15]. Amplicons were sequenced to a mini-
mum depth of 40 reads. Any amplicon that did not reach this 
threshold was sequenced again in a subsequent MiSeq run or 
Sanger sequenced. Single nucleotide variants and insertion/
deletion variants were called using ‘The Genome Analysis 
Toolkit’ (GATK) v.3.6 [16]. The effects of variants were 
predicted using SnpEff v.4.2 [17]. Variants were annotated 
with minor allele frequencies from the Exome Aggregation 
Consortium (ExAC) [18], the 1000 Genomes Project [19], 
and the University of Washington’s Exome Sequencing Pro-
ject (ESP6500) [20] databases. The functional consequences 
of missense variants were predicted in silico using SIFT 
[21], Provean [22], and PolyPhen2 [23].
Classification on pathogenic variants
Nonsynonymous and noncoding variants with a minor 
allele frequency (MAF) of < 0.05 for cases or controls were 
considered rare. All rare variants were queried in ClinVar 
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and published literature, and were classified according to 
the American College of Medical Genetics and Genomics 
guidelines [24].
Variant validation
All rare variants were visually inspected using the Integra-
tive Genomics Viewer [25]. Rare nonsynonymous and non-
coding variants were confirmed by re-extracting DNA from 
blood samples and Sanger sequencing.
Copy number analysis
Cases without pathogenic CDH1 mutations were subse-
quently tested for copy number changes using Multiplex 
Ligation Dependent Probe Amplification (MLPA). The 
SALSA MLPA CDH1 probe-mix (v.C1) was used accord-
ing to the manufacturer’s instructions. Results were analysed 
using Coffalyser.Net software.
Statistical analysis
Statistical tests were performed using R v.3.3.3 [26]. The 
significance of correlation between clinical characteristics 
and mutation status were tested using Fisher’s exact test.
Results
Characteristics of study participants
Germline CDH1 was sequenced for 94 Māori gastric can-
cer patients and 200 healthy matched controls. The cases 
comprised 50 (53%) males and 44 (47%) females. The 
average age of cases at the time of gastric cancer diagnosis 
was 55.5 years (range 17–81 years). Tumour histology was 
available for 81/94 (86.2%) of cases. Out of these 81 cases, 
50 (62%) were diffuse type, 22 (27%) were intestinal type, 
and 9 (11%) were other types. Of the 21 cases diagnosed 
in individuals younger than 45 years, 20 (95%) were dif-
fuse type and one (5%) was unspecified (Fig. 1). The earli-
est intestinal-type tumour was diagnosed in a patient aged 
49 years. The full clinical characteristics of the cases are 
presented in Table 1.
Pathology reports from cases were reviewed for informa-
tion that indicated prior genetic screening. Pathology reports 
from 15 cases described prophylactic gastrectomies, endo-
scopic screening, or noted CDH1 mutation status as a part 
of the clinical pathway. As these procedures are offered to 
CDH1 mutation carriers, it is likely these cases were known 
mutation carriers who had elected prophylactic surgery or 
who had foci of gastric cancer identified during endoscopic 
screening.
Fig. 1  Tumour subtypes by age at diagnosis of gastric cancer in 
cases. NOS not otherwise specified
Table 1  Clinical characteristics of the study cases
NOS, not otherwise specified
Total
n %
Total 94
Gender
 Male 50 53
 Female 44 47
Age at diagnosis (years)
 < 45 21 22
 45–59 32 34
 60–74 30 32
 > 75 11 12
Tumour subtype
 Diffuse 50 53
 Intestinal 22 23
 Other 9 10
 NOS 13 14
Tumour grade
 Well differentiated 4 4
 Moderately differentiated 10 11
 Poorly differentiated 47 50
 NOS 33 35
Tumour site
 Proximal 30 32
 Distal 20 21
 Mixed 4 4
 Oesophageal junction 5 5
 NOS 35 37
Extent
 Local 26 28
 Lymph node involvement 20 21
 Regional spread 7 7
 Metastatic spread 13 14
 NOS 28 30
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The controls comprised 104 (52%) males and 96 (48%) 
females. The average age of the controls was 57.6 years 
(range 19–84 years).
Variants of uncertain significance
Four healthy controls were found to carry one of 
three variants of uncertain significance (c.88C>A 
(p.Pro30Thr), c.1214A>G (p.Asn405Thr), and c.2556G>T 
(p.Glu852Asp); Supplementary Table 3). To our knowledge, 
this is the first time these variants have been reported in the 
Māori population. No variants of uncertain significance were 
identified in the gastric cancer cases.
CDH1 c.88C>A was identified in one healthy control 
aged 56 years. c.88C>A has been reported in population 
databases (MAF ≤ 0.001) and is most commonly classified 
as ‘likely benign’ in ClinVar. In silico prediction tools have 
conflicting interpretations of CDH1 c.88C>A pathogenic-
ity. Notably, germline CDH1 c.88C>A has been reported in 
lobular breast and diffuse gastric cancer patients [27, 28], as 
well as two unrelated individuals with cleft lip with or with-
out cleft palate, a developmental birth defect that is known 
to be overrepresented in CDH1 mutation carriers [29, 30]. 
Additional evidence from in vitro assays indicate that the 
p.Pro30Thr mutation affects E-cadherin protein function and 
its subcellular localisation [30].
CDH1 c.1214A>G (p.Asn405Ser) was identified 
in one healthy control (age 74  years) and c.2556G>T 
(p.Glu852Asp) was identified in two healthy controls (age 
62 and 68 years). Both c.1214A>G and c.2556G>T are very 
rare in population variant databases (MAF < 0.0001) and are 
not described in published literature. In silico predictions 
do not support a pathogenic classification for either of these 
mutations.
Pathogenic mutations
After reviewing all available information regarding the vari-
ants identified in this study, we classified five variants as 
pathogenic mutations (three nonsense, one frameshift, and 
one missense; Supplementary Table 4). The three nonsense 
mutations (c.190C>T (p.Gln64*), c.1792C>T (p.Arg598*), 
and c.2287G>T (p.Glu763*)) and one frameshift muta-
tion (c.2381_2386insC (p.Arg796fs)) were identified in 
four cases each, while the deleterious missense mutation 
(c.2195G>A (p.Arg763Gln)) was identified in a single case 
(Table 2). The nonsense and frameshift mutations are known 
HDGC mutations that had previously been reported in Māori 
families in New Zealand [31]. c.2195G>A is a putative 
HDGC mutation that is located at the intracellular border of 
the cytoplasmic domain of E-cadherin and has been shown 
to create a new acceptor splice site and a large deletion in the 
E-cadherin protein [32]. c.2195G>A had previously been 
shown to be causative of HDGC in two families of northern 
European origin [33]. To our knowledge, this is the first time 
Table 2  Clinical characteristics of Māori gastric cancer patients with pathogenic germline CDH1 mutations
NOS not otherwise specified
a Age at time of diagnosis
b Variant positions are reported in reference to NCBI RefSeq NM_004360.3 (mRNA) and NP_004351.1 (protein)
Identifier Agea Gender Nucleotid  changeb Protein  changeb Subtype Extent Grade Site
Y240 24 Female c.190C>T p.Gln64* Diffuse Local NOS NOS
Y382 29 Male c.190C>T p.Gln64* Diffuse Local NOS Proximal
Y704 48 Female c.190C>T p.Gln64* Diffuse Local NOS NOS
Y647 61 Female c.190C>T p.Gln64* Diffuse Local NOS Distal
Y649 20 Female c.1792C>T p.Arg598* Diffuse Local NOS NOS
Y579 23 Female c.1792C>T p.Arg598* Diffuse Local NOS NOS
Y709 24 Male c.1792C>T p.Arg598* Diffuse Local Poorly differentiated Proximal
Y255 29 Female c.1792C>T p.Arg598* Diffuse Local NOS Proximal
Y616 38 Female c.2195G>A p.Arg732Gln Diffuse Metastatic spread Poorly differentiated NOS
Y435 31 Female c.2287G>T p.Glu763* Diffuse Local Poorly differentiated Proximal
Y670 39 Female c.2287G>T p.Glu763* Diffuse Metastatic spread NOS NOS
Y706 41 Male c.2287G>T p.Glu763* Diffuse Local NOS NOS
Y335 50 Male c.2287G>T p.Glu763* Diffuse Local NOS NOS
Y638 17 Male c.2381_2386insC p.Arg796fs Diffuse Local NOS NOS
Y425 20 Male c.2381_2386insC p.Arg796fs Diffuse Local NOS NOS
Y666 26 Female c.2381_2386insC p.Arg796fs Diffuse Local NOS NOS
Y386 44 Male c.2381_2386insC p.Arg796fs Diffuse Local NOS NOS
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c.2195G>A has been reported in New Zealand Māori. No 
pathogenic mutations were identified in the controls.
Frequency of pathogenic mutations
Overall, pathogenic germline CDH1 mutations were iden-
tified in 17/94 (18%) of the total gastric cancer cases and 
17/50 (34%) of diffuse gastric cancer cases (Table 3). The 
proportion of cases aged less than 45 years at diagnosis with 
a pathogenic germline CDH1 mutation was 14/21 (67%). 
Only 3/73 (4%) of cases with mutations were aged 45 years 
and over (Fig. 2). The average age of diagnosis for mutation 
carriers was 33.2 years (range 17–61), and 60 years (range 
28–81) for non-carriers. Of the pathogenic mutation carri-
ers, 15/17 (88%) were diagnosed with early stage localised 
tumours, presumably subsequent to HDGC family mutation 
screening. The remaining two cases with pathogenic muta-
tions were diagnosed with late stage metastatic disease and 
did not appear to be diagnosed as a result of being a known 
CDH1 mutation carrier.
Our data demonstrates that between 2009 and 2013, 18 
and 34% of Māori gastric cancer and diffuse gastric can-
cer cases, respectively, carried pathogenic germline CDH1 
mutations. However, since the majority of these cases were 
diagnosed as a result of prior familial HDGC screening, 
these figures do not accurately represent the prevalence of 
pathogenic CDH1 mutations in the Māori gastric cancer 
population. Without the targeted interventions offered to 
the 15 cases that were likely diagnosed as a result of being 
a known CDH1 mutation carrier, it is unlikely they would 
have presented until their cancers had progressed and symp-
toms emerged. Accordingly, without prior genetic screening, 
the majority of CDH1 mutation carriers identified during 
this study would have likely presented with advanced dis-
ease at a later date. Accounting for the number of Māori 
CDH1 mutation carriers identified between 1998 and 2008 
(P. Guilford, personal communication) and using a lifetime 
penetrance estimate of 70%, we estimate that in the absence 
of familial HDGC screening, germline CDH1 mutations 
would account for 6% of all advanced Māori gastric cancers 
and 13% of all diffuse-type gastric cancers.
Discussion
To our knowledge, this is the first study that has examined 
the frequency of gastric cancers that are attributable to ger-
mline CDH1 mutations in a specific ethnic group. In keep-
ing with previous studies, we observed a high proportion of 
diffuse gastric cancers, many of which were diagnosed in 
patients less than 45 years of age. Overall, 18% of all cases, 
Table 3  Clinical characteristics of the study cases by mutation status
NOS not otherwise specified
CDH1 
mutation 
positive
CDH1 muta-
tion negative
p value
n % n %
Total 17 18 77 82
Gender
 Male 7 14 43 86
 Female 10 23 34 77 0.296
Age at diagnosis (years)
 < 45 14 67 7 33
 45–59 2 6 30 94
 60–74 1 3 29 97
 > 75 0 0 11 100 < 0.001
Tumour subtype
 Diffuse 17 34 33 66
 Intestinal 0 0 22 100
 Other 0 0 9 100
 NOS 0 0 13 100 < 0.001
Tumour grade
 Well differentiated 0 0 4 100
 Moderately differentiated 0 0 10 100
 Poorly differentiated 3 6 44 94
 NOS 14 42 19 58 < 0.001
Tumour site
 Proximal 4 13 26 87
 Distal 1 5 19 95
 Mixed 0 0 4 100
 Oesophageal junction 0 0 5 100
 NOS 12 34 23 66 0.048
Extent
 Local 15 58 11 42
 Lymph node involvement 0 0 20 100
 Regional spread 0 0 7 100
 Metastatic spread 2 15 11 85
 NOS 0 0 28 100 < 0.001
Fig. 2  Frequency of pathogenic germline CDH1 mutations by age at 
diagnosis of gastric cancer in cases
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34% of cases diagnosed with diffuse-type gastric cancer, 
and 67% of cases diagnosed aged less than 45 years carried 
pathogenic CDH1 mutations. Additionally, we estimate that 
in absence of screening, 6% of all advanced gastric cancer 
and 13% of all advanced diffuse-type gastric cancers in the 
Māori population would carry germline CDH1 mutations.
Whether any of the variants of uncertain significance 
identified in healthy controls in this study impact on E-cad-
herin function and, consequently, have a role in gastric can-
cer predisposition remains to be clarified. In particular, the 
c.88C>A (p.Pro30Thr) mutation will require further evalu-
ation to determine if it is associated with a hereditary cancer 
risk. Given the relative frequency of c.88C>A in the healthy 
population it is unlikely to be associated with an extreme 
risk of disease. However, as c.88C>A has been identified in 
unrelated cleft lip with or without cleft palate cases, and has 
been shown to cause defects in E-cadherin protein function 
and its subcellular localisation in vitro, it is plausible that 
the c.88C>A mutation has a deleterious effect on E-cadherin 
function in vivo and may represent a mutation with a low to 
moderate risk of disease.
It is unclear why the prevalence of pathogenic germline 
CDH1 mutations is so high in the Māori gastric cancer popu-
lation. Founder mutations have been identified as a common 
cause of cancer in some populations. Of note is the Ash-
kenazi Jewish population, for which approximately 2% of 
the general population carry one of three founder mutations 
in the tumour suppressor genes BRCA1 and BRCA2 [34]. 
Mutations in these genes are associated with an increased 
risk of both breast and ovarian cancer [35]. Subsequently, 
approximately 12% of breast cancers [36] and 40% [37] of 
ovarian cancers in the Ashkenazi Jewish population are 
attributable to these specific founder mutations. Similarly, 
a founder mutation in germline CDH1 has previously been 
identified in multiple families from Newfoundland, Canada 
[32]. Interestingly, Newfoundland has an elevated rate of 
gastric cancer compared to the Canadian average and the 
regions these families come from are the highest-risk areas 
within the province [32, 38]. As yet, the exact contribution 
of CDH1 mutations to the high rates of gastric cancer in the 
Newfoundland province is still to be determined.
Similar to the common mutation seen in Newfoundland, 
CDH1 mutations could have arisen as founder mutations 
prior to the Māori migration to New Zealand. However, the 
relatively high number of distinct CDH1 mutations (5 muta-
tions in this study alone) suggests that, rather than being an 
illustration of a simple genetic bottleneck, CDH1 mutations 
may have provided a selective advantage to mutation carriers 
in ancestral Māori populations.
One possible explanation is that CDH1 mutation car-
riers may have a degree of innate resistance to infection 
with Listeria monocytogenes, a food-born pathogen that 
can cause gastroenteritis, meningitis, and miscarriage in 
pregnant women [39, 40]. L. monocytogenes is normally 
internalised into epithelial cells by a process requiring 
the binding of the bacterial protein internalin-A (InlA) 
to the N-terminus of the E-cadherin protein [40]. Some 
truncating E-cadherin mutations produce short soluble 
N-terminal peptides containing the InlA binding site that 
have been shown to act as decoy receptors for invading L. 
monocytogenes in vitro [39]. Alternatively, a reduction in 
functional E-cadherin available in mutation carriers may 
cause changes to the organisation of the cortical actin 
cytoskeleton which, in turn, may impact on the efficiency 
of endocytosis and the internalisation of L. monocytogenes 
or other pathogens [41].
The main purpose of our study was to determine the 
prevalence of pathogenic CDH1 mutations in the Māori 
gastric cancer population. After reviewing the pathology 
reports from gastric cancer cases, the importance and 
impact of genetic screening for Māori became especially 
apparent. Notably, all 15 gastric cancer cases that were 
diagnosed as a result of interventions available to known 
CDH1 mutation carriers were diagnosed with early-stage 
disease and were still alive five years post diagnosis (data 
not shown). In contrast, the two CDH1 mutation carri-
ers who did not appear to be known carriers were both 
diagnosed with late-stage metastatic disease and both died 
shortly after diagnosis. Clearly, clinical genetic screening 
and targeted interventions for CDH1 mutation carriers is 
enabling timely and effective identification and manage-
ment of mutation carriers in known HDGC families. Our 
findings suggest that, ideally, clinical germline CDH1 test-
ing should be incorporated into standard care for all Māori 
who present with early-onset diffuse gastric cancer.
As the most comprehensive study of germline CDH1 
mutations in a specific ethnic group, our study demon-
strates the significant impact pathogenic CDH1 mutations 
have on the high frequency of early-onset diffuse gastric 
cancer cases in the New Zealand Māori population. We 
highlight the importance of clinical genetic screening of 
HDGC families and the potential benefits of genetically 
screening all Māori who present with early-onset diffuse 
gastric cancer.
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